Daniela Voskova

Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia

Wolfgang Kern, Daniela Voskova, Claudia Schoch et al. · Blood · 2004 · 269 citations

Medicine, Hematology, Oncology +16

Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group

Lisa Pleyer, Sonja Burgstaller, Michael Girschikofsky et al. · Annals of Hematology · 2014 · 96 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Stability of leukemia‐associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: Comparison with cytomorphologic, cytogenetic, and molecular genetic findings

Daniela Voskova, Claudia Schoch, Susanne Schnittger et al. · Cytometry Part B Clinical Cytometry · 2004 · 79 citations · Full text

Medicine, Hematology, Molecular Genetics +17

Prognostic impact of early response to induction therapy as assessed by multiparameter flow cytometry in acute myeloid leukemia.

Wolfgang Kern, Daniela Voskova, Claudia Schoch et al. · PubMed · 2004 · 68 citations

Medicine, Hematology, Oncology +14

Azacitidine in patients with WHO-defined AML – Results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group

Lisa Pleyer, Reinhard Stauder, Sonja Burgstaller et al. · Journal of Hematology & Oncology · 2013 · 61 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +9